Zhongzhi Pharmaceutical Holdings Limited (Zhongzhi Pharm) has filed its monthly return for the period ended 30 April 2026, confirming that its share capital structure remained unchanged during the month.

The authorised share capital stayed at 1.56 billion ordinary shares with a par value of HKD 0.01 each, equivalent to HKD 15.60 million. Issued share capital also held steady at 863.60 million ordinary shares, with no treasury shares outstanding and no issuance or cancellation activity recorded in April.

Zhongzhi Pharm affirmed full compliance with the Main Board’s minimum public float requirement, maintaining at least 25% of its issued shares in public hands.

The company reported no movements under share option schemes, warrants, convertibles, or other equity-linked instruments during the month. All regulatory confirmations required under Hong Kong Listing Rule 13.25C have been provided by Director Lai Zhi Tian, who submitted the return on 4 May 2026.